Related Experiment Video
Updated: Jan 25, 2026
Assay of Adhesion Under Shear Stress for the Study of T Lymphocyte-Adhesion Molecule Interactions
Published on: June 29, 2016
Vascular cell adhesion molecule 1 in patients with severe osteoarthritis of the hip : A prospective cross-sectional
Bastian Oppl1, Christian Datz2, Ursula Huber-Schönauer2
11st Medical Department, Hanusch Hospital, Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, Heinrich Collin-Str. 30, 1140, Vienna, Austria.
Insights
This study investigated vascular cell adhesion molecule 1 (VCAM-1) as a biomarker for hip osteoarthritis (OA). Elevated VCAM-1 serum levels did not significantly differentiate severe hip OA patients from controls, indicating it
Area of Science:
- Orthopedics and Rheumatology
- Biomarker Discovery
- Molecular Medicine
Background:
- Hip osteoarthritis (OA) is a common cause of disability.
- Clinical risk factors and biomarkers for hip OA are limited.
- Vascular cell adhesion molecule 1 (VCAM-1) is a potential biomarker for joint OA.
Purpose of the Study:
- To determine if elevated serum VCAM-1 levels are present in patients with severe hip OA.
- To validate VCAM-1 as a potential biomarker for identifying individuals with severe hip OA.
Main Methods:
- Prospective, multicenter, cross-sectional study design.
- Inclusion of patients undergoing hip arthroplasty and a control cohort.
- Serum VCAM-1 analysis using enzyme-linked immunosorbent assay (ELISA).
Main Results:
- Serum VCAM-1 concentrations were 8% higher in hip OA patients than controls.
- This difference did not reach statistical significance (P=0.4839).
- VCAM-1 levels were 818 ng/ml in OA patients vs. 759 ng/ml in controls.
Conclusions:
- Serum VCAM-1 levels do not reliably distinguish severe hip OA patients from controls.
- VCAM-1 is not a suitable biomarker for diagnosing severe hip OA in this cohort.
- Further research may explore other biomarkers for hip OA detection.
Background:
Osteoarthritis (OA) of the hip is a frequent and debilitating joint disease. Only few clinical risk factors for hip OA are established and clinically applicable biomarkers to identify patients at risk are still lacking. The glycoprotein vascular cell adhesion molecule 1 (VCAM-1) is expressed by chondrocytes and synovial tissue and was a predictive marker for development of severe large joint OA in a previous study.
Objective:
It was tested whether increased serum levels of VCAM-1 are prevalent in patients with severe OA of the hips.
Methods:
In this prospective, multicenter, cross-sectional study, risk factors of severe hip OA were investigated in patients scheduled for hip joint arthroplasty and 100 patients were randomly selected for validation of VCAM-1 as a potential biomarker for hip OA. Serum samples were analyzed by an enzyme-linked immunosorbent assay and compared with a sex and age-matched control cohort.
Results:
The groups were similar in age, gender ratio and prevalence of diabetes. Serum concentrations of VCAM-1 were 8% higher in OA patients compared to controls, without reaching statistical significance (818 ng ml-1, 95% confidence interval, CI 746-891 ng ml-1 versus 759 ng m-1, 95% CI 711-807 ng ml-1; P = 0.4839).
Conclusion:
The results of this study show that serum concentrations of VCAM-1 cannot distinguish patients with severe hip OA from age and sex-matched controls.
Related Concept Videos
01:50Cross-Sectional Research
01:31Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
01:20Cell Adhesion Molecules - Types and Functions
CAM Families
The Integrin family of proteins is primarily involved...
01:26Profile Leveling and Cross Sections
01:16Spinal Cord: Cross-sectional Anatomy
Gray Matter and its Components
Central to the gray matter is...
01:14Adhesion
Capillary action is a result of water’s adhesive tendencies. When a narrow...